GlobeNewswire Inc | Sep 2, 2021 07:00AM EDT

September 02, 2021

DALLAS, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Instil) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in two upcoming investor conferences in September:

Morgan Stanley 19th Annual Global Healthcare ConferenceFireside Chat: Thursday, September 9 at 2:00 p.m. ET

Bairds 2021 Virtual Global Healthcare ConferenceCompany Presentation: Tuesday, September 14 at 5:30 p.m. ET

A live webcast, if recorded, of each presentation can be accessed under News & Events in the Investors section of the Companys website at www.instilbio.com. The archived webcast will be available on the Companys website shortly after the event.

About Instil Bio

Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. The Company has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies. Using the Companys proprietary, optimized, and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors as well as ITIL-306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information visit www.instilbio.comand LinkedIn.

Contacts:

Brendan PayneStern Investor Relations1-212-362-1200brendan.payne@sternir.com

Media Contact:1-833-446-7845 Ext. 1009mediarelations@instilbio.com